TIGER-1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-small Cell Lung Cancer (NSCLC)

SUMMARY

N/A

COH Protocol Number : 15053

ClinicalTrials.gov Number : NCT02186301

Principal Investigator : Reckamp, Karen M.D.

Sponsor : Clovis Oncology, Inc.

BRIEF ELIGIBILITY CRITERIA :

Eligible Ages : >=18

Gender : Either

Minimum Performance Status : ECOG/SWOG:1

Treatment Intent : Non-Adjuvant treatment

Prior Chemotherapy :

Brain Metastases :

Measurable Disease :